
MAIA Biotechnology, Inc.
NYSE · Pharmaceutical Preparations
Company Overview
A concise company profile alongside the latest public filing activity.
MAIA Biotechnology is a clinical-stage biopharmaceutical company developing telomere-targeting therapies for cancer treatment, with its lead candidate THIO being studied for non-small cell lung cancer and other solid tumors.
Company profile sourced from SEC filings.
Corporate Insider Trades
Open-market purchases and sales by directors, officers, and other company insiders.
| Insider | Type | Value | Shares / Price | Date |
|---|---|---|---|---|
| Guerrero RamiroDirector | Buy | $2K | 1,794at $1.33 | Aug 24, 2026 |
Source: SEC EDGAR Form 4 filings
Congressional Trades
Recent disclosures by members of the U.S. House and Senate.
Source: Senate eFD and House Clerk STOCK Act disclosures
Get notable MAIA activity by email
Free alerts for the insider and congressional trades worth watching.
For informational purposes only, not investment advice. Filings can be delayed, corrected, or amended. Trading activity alone does not predict future performance.